Inhaled Corticosteroids on Airway Smooth Muscle in Asthma

Asthma Clinical Trial

Official title:

The Effect of Inhaled Corticosteroids (ICS) on Airway Smooth Muscle in Asthma

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT00661973
• Other study ID #: 2007-006664-29
• Secondary ID: 07/H0803/239
• Status: Withdrawn
• Phase: Phase 4
• Start date: April 2008
• Est. completion date: March 2011

Study information

• Verified date: September 2019
• Source: Imperial College London
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main objective is to evaluate how treatment with inhaled corticosteroids (ICS) affects the characteristics of airway smooth muscle (ASM) cells from asthmatic subjects. Our hypothesis is that airway smooth muscle cell dysfunction plays an important role in the pathogenesis of asthma, and that treatment with inhaled corticosteroids reverses the abnormalities in airway smooth muscle cell function.

Description:

Aims and Objectives

Most of the work published to date on the effect of steroids on ASM has been carried out in animal models or in in vitro experiments. We would like to evaluate in vivo whether abnormalities in ASM function respond to ICS. Because ASM cells can be obtained from bronchial biopsies obtained via bronchoscopy, we will examine endobronchial biopsies from corticosteroid-naïve, mild asthmatic subjects. In particular, we will examine whether ICS have any effect ASM mass, proliferation and expression of different contractile proteins (α-actin and myosin) and chemokines, and will assess in vitro the response of ASM cells to stimulation by TGF-β and IL-1β. We will also examine the effect of dexamethasone on chemokine release and induced proliferation in vitro before and after treatment with ICS.

We will examine the effect of inhaled corticosteroids in 12 subjects with mild asthma. The subjects will be studied during a baseline period and again after receiving treatment with inhaled corticosteroid therapy with Budesonide Turbohaler (400 ug bd) for 4 weeks. The results of these two periods will be compared.

There will be 5 study visits. In the first two visits, the subjects will undergo spirometry with reversibility testing, a methacholine challenge test, skin prick tests and IgE levels, measurement of exhaled nitric oxide, and subjects will complete an Asthma Control Questionnaire and an Asthma Quality of Life Questionnaire. The third visit will be the day admission for the bronchoscopy. They will be given asthma control diary cards to complete during the 4-week treatment with ICS and receive their ICS turbohaler. At visit 4, they will have repeat spirometry and methacholine challenge to assess if there has been a change secondary to treatment with ICS. The final visit will be for the second bronchoscopy, when the dairy card and ICS inhaler will be collected, and the subjects will complete the Asthma Control and Quality of Life questionnaire.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: March 2011
• Est. primary completion date: December 2010
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Physician diagnosis of asthma

• Age 18-60

• Intermittent asthma symptoms < once/week

• FEV1>80% of predicted

• Not on inhaled corticosteroid therapy

Exclusion Criteria:

• Previous long-term use of inhaled corticosteroids (within 1 year of entry into study)

• Past history of hypersensitivity to budesonide

• Current smokers, or less than 3 years since quitting smoking

• Less than 4 weeks from an exacerbation

• On steroid-sparing agent or immunosuppressant such as azathioprine, methotrexate and ciclosporin

• Concomitant anti-IgE therapy

• Pregnancy

• Previous bronchoscopy within three months of this study

Related Conditions & MeSH terms

• Asthma

Intervention

Drug:
• budesonide
inhaled budesonide (turbohaler) 400 micrograms twice a day for 4 weeks

Locations

Country	Name	City	State
United Kingdom	Asthma lab, Royal Brompton Hospital, Sydney Street	London

Sponsors (2)

Lead Sponsor	Collaborator
Imperial College London	Royal Brompton & Harefield NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in ASM mass, proliferation and migration after ICS therapy; changes in chemokine release after ICS therapy		4 weeks
Secondary	Changes in sub-basement membrane thickness and inflammatory cell count after ICS therapy		4 weeks